FDA PHARMACY RULES / 06
What do FDA pharmacy rules mean for Wolverine?
FDA once put both parts of BPC-157 TB-500 in a safety-concern group for raw drug ingredients, and both requests have since been withdrawn. FDA hasn't said what that means for your pharmacy, and this isn't legal advice.
Contents
What does FDA's safety group mean for both parts?
FDA calls 503A its rule for medicine a local pharmacy makes for one named patient. FDA's page, current as of April 22, 2026, says the nominations for both Wolverine ingredients were withdrawn; both are no longer in Category 2, and FDA does not spell out what a local pharmacy may make from them. On September 29, 2023, FDA added BPC-157 free base and BPC-157 acetate [15][16]. Those are two chemical forms used to prepare the same drug ingredient, and FDA treats both alike for your access. The agency also added TB-500, the short piece cut from Thymosin Beta-4.
For Category 1, FDA often waits before acting against a pharmacy while it reviews an ingredient [17]. That promised wait does not cover Category 2. FDA hasn't said whether a pharmacy that mixes either Wolverine ingredient still risks FDA action now that the requests were withdrawn. The usual federal policy gives you no clear answer on routine access.
FDA warns that the immune system may react to these protein pieces [15][16]. It also says unwanted matter in a product can be hard to find. Neither BPC-157 nor the TB-500 piece has FDA approval. The BPC-157 part and the mix have no approved use. FDA still lists that safety warning beside each ingredient.
Approval to sell a finished drug is one FDA decision. Permission for a pharmacy to use a raw ingredient is another [17]. FDA has given neither kind of permission to these parts.
Did the past FDA meeting change the rule?
FDA set a public meeting for July 23-24, 2026. Its agenda named BPC-157 free base, BPC-157 acetate, TB-500 free base, and TB-500 acetate [18]. Free base and acetate are chemical forms of the same two substances, not four different treatments. The panel considered pharmacy use under 503A, the one-patient pharmacy rule, and FDA staff had proposed against adding them. An agenda is not a ruling.
FDA, not the panel, makes the final rule after hearing the panel's advice [17]. Because the meeting date has passed, the limit of this FDA.gov source matters to you: it does not report what the panel said. It also doesn't show whether FDA later acted [18]. The newest status supported here is FDA's page current as of April 22, 2026: both requests withdrawn, with the safety warning still listed.
The July 2026 agenda shows FDA had planned a review. It does not prove approval or wider access. Until a later FDA decision is confirmed, you can't treat the meeting as a change in the rule.
What must a pharmacy check before making BPC-157?
Can a pharmacy prepare one patient's medicine?
FDA put BPC-157 in Category 2 under 503A on September 29, 2023 [15]. That rule covers medicine a local pharmacy makes for one named patient. FDA does not promise to hold back action for this safety group. A raw ingredient must pass one of three tests: meet an official drug standard, appear in an approved drug, or sit on FDA's allowed list [17]. BPC-157 meets none of those three tests, and the agency is silent on what its withdrawn request means for a pharmacy.
The same pharmacy rule covers the TB-500 piece. A doctor or another person licensed to prescribe must first examine you and write a valid prescription. Under 503A, the state-licensed pharmacy can make medicine for that named person. A 503B site is registered with FDA and may make larger batches [17]. That larger-batch rule does not let the site use a barred ingredient.
You may meet the person who prescribes by video. A real exam and valid prescription are still required [17]. A video visit doesn't change which drug ingredients a pharmacy may use.
The raw ingredient must still qualify under the 503A/503B rules [17]. FDA's safety concern is still on record for both parts, and FDA hasn't said whether they can enter routine 503A use. This page names no seller, clinic, or amount for a person.
Does FDA treat Wolverine as its own drug?
Why does FDA warn about each part?
The pair has no separate FDA class. As of September 29, 2023, each part was a Category 2 raw drug ingredient under 503A, the one-patient pharmacy rule; FDA's page current as of April 22, 2026 lists both requests as withdrawn [15][16]. FDA says ingredients in that Category 2 group may carry serious safety risks. It does not promise to hold back action against pharmacies that use them.
What do the rules mean for a pharmacy making Wolverine?
There is no approved Wolverine product. Section 503A covers medicine made for one named patient by a doctor or state-licensed pharmacy. Section 503B covers FDA-registered sites that make larger batches [17]. The second rule matters because some medicine comes from those larger sites, but it doesn't erase the limit on ingredients.
Neither part sits in the Category 2 table any longer, yet FDA hasn't told pharmacies whether using one could still bring agency action [15][16]. FDA's safety warning on both is more than a note that it discourages the mix. The Wolverine legal status and FDA 503A category rests on two unapproved ingredients, though state law may add other rules. These facts can't replace medical or legal advice, and nothing here offers the mix for sale.